Therapeutic drug monitoring for valproate: deriving a novel formula for calculation of free concentration
- PMID: 39150536
- PMCID: PMC11458675
- DOI: 10.1007/s00228-024-03741-2
Therapeutic drug monitoring for valproate: deriving a novel formula for calculation of free concentration
Abstract
Background: Monitoring free valproate concentrations, as with other highly protein-bound anticonvulsants, is essential in clinical situations where protein binding may be disrupted. Conversion of measured total concentrations to approximate free concentrations offers a cost-effective alternative. This study evaluated the relationship between total and free valproate concentrations for discordance and the impact of key determinants. A novel formula was devised that incorporates significant variables.
Methods: A multicentre, cross-sectional observational analytical study included 101 subjects 18 years and older using valproate for 6 months or longer. Participants were recruited from private and public sector healthcare settings from primary to tertiary level in, South Africa, during 2017-2019.
Results: Free valproate concentrations could be measured for 84 subjects. Discordance for concomitant total and free valproate concentrations was 79.1%. Among 19 participants with elevated free concentrations, 15 (78.9%) had total valproate concentrations within the recommended reference range. Calculations based on the study-derived formula were more accurate in predicting free valproate concentration than previously proposed methods.
Conclusion: This study proposes that the novel formula for calculating free valproate enables more accurate prediction.
Keywords: Calculation; Formula; Free concentration; Therapeutic drug monitoring; Total concentration; Valproate.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures




Similar articles
-
Valproate Protein Binding Is Highly Variable in ICU Patients and Not Predicted by Total Serum Concentrations: A Case Series and Literature Review.Pharmacotherapy. 2017 Apr;37(4):500-508. doi: 10.1002/phar.1912. Epub 2017 Mar 16. Pharmacotherapy. 2017. PMID: 28173638 Review.
-
A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug-Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy.CNS Drugs. 2020 Jun;34(6):661-672. doi: 10.1007/s40263-020-00726-4. CNS Drugs. 2020. PMID: 32350749 Free PMC article. Clinical Trial.
-
Determinants of free serum valproate concentration: A prospective study in patients on divalproex sodium monotherapy.Seizure. 2018 Jul;59:24-27. doi: 10.1016/j.seizure.2018.04.012. Epub 2018 Apr 23. Seizure. 2018. PMID: 29730272 Clinical Trial.
-
[Therapeutic drug monitoring of valproate].Therapie. 2010 May-Jun;65(3):233-40. doi: 10.2515/therapie/2010029. Epub 2010 Aug 11. Therapie. 2010. PMID: 20699076 Review. French.
-
Pharmacokinetic Variability During Long-Term Therapeutic Drug Monitoring of Valproate, Clobazam, and Levetiracetam in Patients With Dravet Syndrome.Ther Drug Monit. 2020 Oct;42(5):744-753. doi: 10.1097/FTD.0000000000000781. Ther Drug Monit. 2020. PMID: 32558674
References
-
- Rahman M, Awosika AO, Nguyen H (2024) Valproic acid. StatPearls Publishing, Treasure Island, FL - PubMed
-
- Nasreddine W, Dirani M, Atweh S, Makki A, Beydoun A (2018) Determinants of free serum valproate concentration: a prospective study in patients on divalproex sodium monotherapy. Seizure 59:24–27. 10.1016/j.seizure.2018.04.012 - PubMed
-
- Patsalos P, Zugman M, Lake C, James A, Ratnaraj N, Sander J (2017) Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: a comparison of free non-protein-bound concentrations. Epilepsia 58(7):1234–1243. 10.1111/epi.13802 - PubMed
-
- Musteata FM (2017) Measuring and using free drug concentrations: has there been ‘real’ progress? Bioanalysis 9(10):767–769. 10.4155/bio-2017-0053 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources